Nemolizumab
Nemolizumab, sold under the brand name Nemluvio, is a medication for the treatment of prurigo nodularis.[2] It is a monoclonal antibody that blocks the interleukin-31 receptor A.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL31RA |
| Clinical data | |
| Trade names | Nemluvio |
| Other names | CIM-331, CD14152, nemolizumab-ilto |
| License data |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Proteolytic enzymes |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[3]
Nemolizumab was approved for medical use in the United States in August 2024.[4]
Medical uses
Nemolizumab is indicated for the treatment of adults with prurigo nodularis.
Society and culture
Names
Nemolizumab is the international nonproprietary name.[5]
References
- ^ "Nemluvio- nemolizumab-ilto injection, powder, lyophilized, for solution". DailyMed. 13 August 2024. Retrieved 5 September 2024.
- ^ Spreitzer H (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).
{{cite journal}}: CS1 maint: unrecognized language (link) - ^ "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.
- ^ "Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Adult Patients Living With Prurigo Nodularis" (Press release). Galderma. 13 August 2024. Retrieved 14 August 2024 – via Business Wire.
- ^ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 74". WHO Drug Information. 29 (3). hdl:10665/331070.
Further reading
- Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. (October 2023). "Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis". The New England Journal of Medicine. 389 (17): 1579–1589. doi:10.1056/NEJMoa2301333. PMID 37888917.
External links
- Clinical trial number NCT04501666 for "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov
- Clinical trial number NCT04501679 for "A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov
Lua error in mw.title.lua at line 346: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |